Jonathan R G Etnel1, Pepijn Grashuis1, Simone A Huygens1,2, Begüm Pekbay1, Grigorios Papageorgiou1,3, Willem A Helbing4, Jolien W Roos-Hesselink5, Ad J J C Bogers1, M Mostafa Mokhles1, Johanna J M Takkenberg1. 1. Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands (J.R.G.E., P.G., S.A.H., B.P., G.P., A.J.J.C.B., M.M.M., J.J.M.T.). 2. Erasmus School of Health Policy & Management, ErasmusUniversity Rotterdam, The Netherlands (S.A.H.). 3. Department of Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands (G.P.). 4. Division of Cardiology, Department of Pediatrics, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands (W.A.H.). 5. Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands (J.W.R.-H.).
Abstract
BACKGROUND: To support decision-making in aortic valve replacement in children and adults, we provide a comprehensive overview of outcome after the Ross procedure. METHODS AND RESULTS: A systematic search was conducted for publications reporting clinical outcome after the Ross procedure, published between January 1, 2000, and November 22, 2017. Reported event rates and time-to-event data were pooled and entered into a microsimulation model to calculate life expectancy and lifetime event risk. Ninety-nine publications were included (13 129 patients; total follow-up: 93 408 patient-years, pooled mean follow-up: 7.9±5.3 years). Pooled mean age at surgery was 9.4±5.5 years for children and 41.9±11.4 for adults. For children and adults, respectively, pooled early mortality risk was 4.19% (95% CI, 3.21-5.46) and 2.01% (95% CI, 1.44-2.82), late mortality rate was 0.54%/y (95% CI, 0.42-0.70) and 0.59%/y (95% CI, 0.46-0.76), autograft reintervention 1.28%/y (95% CI, 0.99-1.66) and 0.83%/y (95% CI, 0.68-1.01), and right ventricular outflow tract reintervention 1.97%/y (95% CI, 1.64-2.36) and 0.47%/y (95% CI, 0.37-0.59). Pooled thromboembolism and bleeding rates were low and comparable to the general population. Lifetime risks of autograft and right ventricular outflow tract reintervention were, respectively, 94% and 100% for children and 49% and 19% for a 45-year-old. Estimated life expectancy after surgery was 59 years for children (general population: 64 years) and 30 years for a 45 years old (general population: 31 years). CONCLUSIONS: Through excellent survival and avoidance of the burden of anticoagulation, the Ross procedure provides a unique opportunity for patients whose preferences do not align with the outcome provided by mechanical valve replacement and for growing children who also benefit from autograft diameter increase along with somatic growth. On the downside, almost all pediatric and many adult Ross patients will require a reintervention in their lifetime.
BACKGROUND: To support decision-making in aortic valve replacement in children and adults, we provide a comprehensive overview of outcome after the Ross procedure. METHODS AND RESULTS: A systematic search was conducted for publications reporting clinical outcome after the Ross procedure, published between January 1, 2000, and November 22, 2017. Reported event rates and time-to-event data were pooled and entered into a microsimulation model to calculate life expectancy and lifetime event risk. Ninety-nine publications were included (13 129 patients; total follow-up: 93 408 patient-years, pooled mean follow-up: 7.9±5.3 years). Pooled mean age at surgery was 9.4±5.5 years for children and 41.9±11.4 for adults. For children and adults, respectively, pooled early mortality risk was 4.19% (95% CI, 3.21-5.46) and 2.01% (95% CI, 1.44-2.82), late mortality rate was 0.54%/y (95% CI, 0.42-0.70) and 0.59%/y (95% CI, 0.46-0.76), autograft reintervention 1.28%/y (95% CI, 0.99-1.66) and 0.83%/y (95% CI, 0.68-1.01), and right ventricular outflow tract reintervention 1.97%/y (95% CI, 1.64-2.36) and 0.47%/y (95% CI, 0.37-0.59). Pooled thromboembolism and bleeding rates were low and comparable to the general population. Lifetime risks of autograft and right ventricular outflow tract reintervention were, respectively, 94% and 100% for children and 49% and 19% for a 45-year-old. Estimated life expectancy after surgery was 59 years for children (general population: 64 years) and 30 years for a 45 years old (general population: 31 years). CONCLUSIONS: Through excellent survival and avoidance of the burden of anticoagulation, the Ross procedure provides a unique opportunity for patients whose preferences do not align with the outcome provided by mechanical valve replacement and for growing children who also benefit from autograft diameter increase along with somatic growth. On the downside, almost all pediatric and many adult Ross patients will require a reintervention in their lifetime.
Entities:
Keywords:
aortic valve replacement; clinical outcome; meta-analysis; microsimulation; pulmonary autograft; the Ross procedure
Authors: Maria von Stumm; Tatjana Sequeira-Gross; Johannes Petersen; Shiho Naito; Lisa Müller; Christoph Sinning; Evaldas Girdauskas Journal: Cardiovasc Diagn Ther Date: 2021-04
Authors: Claudia Cattapan; Mila Della Barbera; Arben Dedja; Piero Pavan; Giovanni Di Salvo; Jolanda Sabatino; Martina Avesani; Massimo Padalino; Alvise Guariento; Cristina Basso; Vladimiro Vida Journal: J Clin Med Date: 2022-06-28 Impact factor: 4.964
Authors: Alexander Horke; Igor Tudorache; Günther Laufer; Martin Andreas; Jose L Pomar; Daniel Pereda; Eduard Quintana; Marta Sitges; Bart Meyns; Filip Rega; Mark Hazekamp; Michael Hübler; Martin Schmiady; John Pepper; U Rosendahl; Artur Lichtenberg; Payam Akhyari; Ramadan Jashari; Dietmar Boethig; Dmitry Bobylev; Murat Avsar; Serghei Cebotari; Axel Haverich; Samir Sarikouch Journal: Eur J Cardiothorac Surg Date: 2020-11-01 Impact factor: 4.191
Authors: Alexander Horke; Dmitry Bobylev; Murat Avsar; Bart Meyns; Filip Rega; Mark Hazekamp; Michael Huebler; Martin Schmiady; Ioannis Tzanavaros; Robert Cesnjevar; Anatol Ciubotaru; Günther Laufer; Daniel Zimpfer; Ramadan Jashari; Dietmar Boethig; Serghei Cebotari; Philipp Beerbaum; Igor Tudorache; Axel Haverich; Samir Sarikouch Journal: Eur J Cardiothorac Surg Date: 2020-10-01 Impact factor: 4.191
Authors: Lucas Van Hoof; Peter Verbrugghe; Elizabeth A V Jones; Jay D Humphrey; Stefan Janssens; Nele Famaey; Filip Rega Journal: Front Cardiovasc Med Date: 2022-02-09
Authors: Johanna Schlein; Barbara Elisabeth Ebner; Ralf Geiger; Paul Simon; Gregor Wollenek; Anton Moritz; Andreas Gamillscheg; Eva Base; Günther Laufer; Daniel Zimpfer Journal: Interact Cardiovasc Thorac Surg Date: 2021-08-18